What is HC Wainwright’s Estimate for Evotec Q1 Earnings?

Evotec SE (NASDAQ:EVO) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Evotec in a research report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of $0.01 for the quarter. The consensus estimate for Evotec’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec’s Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.00 EPS, FY2028 earnings at $0.60 EPS and FY2029 earnings at $0.72 EPS.

Separately, Deutsche Bank Aktiengesellschaft upgraded Evotec from a “sell” rating to a “hold” rating in a research note on Thursday, April 24th.

Evotec Price Performance

EVO stock opened at $4.33 on Friday. The firm has a 50-day moving average of $3.61 and a 200 day moving average of $4.16. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. Evotec has a 1 year low of $2.84 and a 1 year high of $5.68.

Hedge Funds Weigh In On Evotec

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new stake in shares of Evotec in the 4th quarter worth approximately $27,000. CSS LLC IL purchased a new stake in shares of Evotec during the fourth quarter valued at $50,000. Bank of America Corp DE increased its holdings in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new position in Evotec in the 4th quarter worth about $166,000. Finally, ABC Arbitrage SA bought a new position in Evotec during the 1st quarter valued at about $260,000. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.